Spotlight On... Freshly unearthed data from key PhII trial sends shares plummeting for Vericel; Pfizer reports positive PhIII data; Metabomed raises $18M; and more...

Cambridge-based Vericel Corp. ($VCEL) has seen its shares plunge back down to earth today after previously unreleased details of its key cell therapy study showed the trial's ostensible success was not as promising as investors had first hoped. The company had been riding on a high for the past month as shares spiked to their highest levels in more than two years, coming after it posted positive Phase II results for its experimental treatment ixmyelocel-T. But the newly disclosed data shows that, while it met the primary endpoint of reducing the total number of deaths and other outcomes in patients with advanced ischemic dilated cardiomyopathy, the trial in fact failed to meet some secondary goals, such as a measure of the duration of time to the first event, the size of the left ventricle cavity and the distance a patient could walk within 6 minutes. In all those measurements, the difference between patients who received the therapy and those on placebo was not statistically significant. Vericel's stock dropped by about a third on the news. Story

@FierceBiotech: Venter's Human Longevity firm raises $220M with help from Celgene, Illumina. Article | Follow @FierceBiotech

@JohnCFierce: Miss our story on  being accused of misrepresenting its data on rociletinib? Report | Follow @JohnCFierce

> Pfizer ($PFE) says it garnered positive data from a Phase III study of tofacitinib (Xeljanz) in psoriatic arthritis.  Release

> Israeli cancer metabolism company Metabomed has completed its Series A, bringing the total to $18 million. Existing investors include MS Ventures, Boehringer Ingelheim Venture Fund, Pontifax Fund, and the Technion Research and Development Foundation. New investors Pfizer and Arkin Holdings also joined the round. Release

Medical Device News

@FierceMedDev: Edwards up 13% on Sapien TAVR data in intermediate-risk heart patients. Report | Follow @FierceMedDev

> Plastic-softening chemicals in medical devices could lead to brain problems in kids: Scientists. Article

Pharma News

@FiercePharma: Allergy battle goes young as GSK's Flonase, Sanofi's Nasacort roll out kid-labeled OTC sprays. FiercePharmaMarketing story | Follow @FiercePharma

@CarlyHFierce: Drugmakers see no marketing leverage from FDA biosim guidelines. More from FiercePharmaMarketing | Follow @CarlyHFierce

> Valeant moves quickly to slash jobs, beginning with Addyi, dermatology sales reps. Report

> Biogen, Samsung accuse AbbVie of evergreening Humira patents to block biosims. Story

> It's a Pfizer vs. Obama matchup as Treasury suits up to fight Allergan merge. Article

Pharma Manufacturing News

> Drug company may kill NC plant project over transgender issue. More

> PuraCap snags second new production site in a week. Report

> Gilead contractor PharmaChem starts $120M Bahamas expansion. Story

> Sun closing Ranbaxy plant in Ireland. Item

> Rusan plant in India remains under EU ban due to persistent GMP problems. Article

Drug Delivery News

> Nanoparticle 'cluster-bomb' penetrates tumors to reduce chemo doses. Report

> Celator raises $40M through common stock offering to support its liposomal cancer candidate. More

> India's Rusan Pharma opens transdermal patch plant in Gujarat. Story

> MIT team invents machine for making personalized drugs 'on demand.' Item

> Augmenix touts study of its rectal spacer to cut side effects of prostate cancer radiotherapy. Article

Pharma Asia News

> Alibaba Health drops China online pharmacy plans, blames complex regulatory environment. Report

> Samsung Bioepis aims at AbbVie Humira patents in U.K. lawsuit. Story

> Chugai, PharmaMar post positive blood cancer results for new sea squirt drug. Article

> Indian pharma to face U.S. headwinds, but growth to remain 'stable.' More

> Australia's biotech industry sings Korea's praises, asks for more tie-ups. Item

Suggested Articles

The data, from two patients with severe blood disorders, are "promising” for what could be a one-and-done treatment, Cantor Fitzgerald analysts wrote.

The fund will back pharma companies as well as developers of medtech products and providers of outsourced services.

The money will fund work to develop polymers in multiple indications and an associated U.S. expansion.